FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 6.1% in March

FibroGen, Inc. (NASDAQ:FGEN) saw a significant decrease in short interest in March. As of March 31st, there was short interest totalling 5,190,000 shares, a decrease of 6.1% from the March 15th total of 5,530,000 shares. Based on an average daily volume of 2,740,000 shares, the short-interest ratio is currently 1.9 days. Approximately 5.7% of the company’s stock are short sold.

Insider Activity

In other FibroGen news, CEO Thane Wettig bought 50,000 shares of FibroGen stock in a transaction dated Thursday, March 7th. The stock was bought at an average price of $1.91 per share, for a total transaction of $95,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 470,178 shares of the company’s stock, valued at $898,039.98. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 2.39% of the company’s stock.

Hedge Funds Weigh In On FibroGen

Institutional investors have recently bought and sold shares of the stock. Altshuler Shaham Ltd bought a new position in FibroGen during the fourth quarter valued at about $28,000. Royal Bank of Canada raised its holdings in FibroGen by 45.3% during the third quarter. Royal Bank of Canada now owns 2,314 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 721 shares in the last quarter. Dark Forest Capital Management LP bought a new position in FibroGen during the first quarter valued at about $47,000. Tower Research Capital LLC TRC raised its holdings in FibroGen by 231.2% during the first quarter. Tower Research Capital LLC TRC now owns 3,385 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 2,363 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of FibroGen in the second quarter valued at about $39,000. 72.71% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. According to data from MarketBeat.com, FibroGen currently has an average rating of “Hold” and an average price target of $17.00.

FibroGen Trading Down 2.3 %

Shares of NASDAQ:FGEN opened at $1.27 on Thursday. FibroGen has a 1 year low of $0.33 and a 1 year high of $20.90. The business has a fifty day simple moving average of $1.98 and a 200 day simple moving average of $1.19. The firm has a market cap of $125.44 million, a price-to-earnings ratio of -0.43 and a beta of 0.70.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The business had revenue of $27.14 million during the quarter, compared to the consensus estimate of $40.00 million. On average, sell-side analysts forecast that FibroGen will post -1.09 EPS for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.